—  Adds an ultra-premium brand to TerrAscend's global portfolio of operations across multiple U.S. States, Canada and the EU.--- Daniel Wacks and Jeremy Cohen to continue leading State Flower TORONTO, Aug. 28, 2019

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to participate in a panel discussion at Citi's 14th Annual Biotech Conference in Boston, MA

IRVINE, Calif., Aug. 28, 2019 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to participate at the 4th Annual Dougherty & Company Institutional Investor Conference being held September 5, 2019 at the Millennium Hotel in M

SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in two upcoming investor conferences. 

ADDIS ABABA, Ethiopia and PLYMOUTH MEETING, Pa., Aug. 28, 2019 /PRNewswire/ -- A collaborative project from the National Comprehensive Cancer Network® (NCCN&r

CARLSBAD, Calif., Aug. 28, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:2019 Wells Fargo Healthcare Conference on Thursday, September 5, 2019 in

VANCOUVER, Aug. 28, 2019 /PRNewswire/ - Choom™ (CSE: CHOO; OTCQB: CHOOF), an emerging adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that an Alberta provincially approved cannabis retail licensee ("Licensee") is open

REDWOOD CITY, Calif., Aug. 28, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain conditions, today announced that it has completed patient enrollment in its prospective, multicenter Randomized Controlled Trial (RCT) for the treatment of chronic pain

PRINCETON, N.J., Aug. 28, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has received a positive recommendation from the independent Data Monitoring Committee (DMC)

WALTHAM, Mass., Aug. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in four upcoming investor conferences. The details for the four conferences are: